Literature DB >> 26392505

Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits.

Shay Weiss1, Zeev Altboum1, Itai Glinert1, Josef Schlomovitz1, Assa Sittner1, Elad Bar-David1, David Kobiler1, Haim Levy2.   

Abstract

Respiratory anthrax is a fatal disease in the absence of early treatment with antibiotics. Rabbits are highly susceptible to infection with Bacillus anthracis spores by intranasal instillation, succumbing within 2 to 4 days postinfection. This study aims to test the efficiency of antibiotic therapy to treat systemic anthrax in this relevant animal model. Delaying the initiation of antibiotic administration to more than 24 h postinfection resulted in animals with systemic anthrax in various degrees of bacteremia and toxemia. As the onset of symptoms in humans was reported to start on days 1 to 7 postexposure, delaying the initiation of treatment by 24 to 48 h (time frame for mass distribution of antibiotics) may result in sick populations. We evaluated the efficacy of antibiotic administration as a function of bacteremia levels at the time of treatment initiation. Here we compare the efficacy of treatment with clarithromycin, amoxicillin-clavulanic acid (Augmentin), imipenem, vancomycin, rifampin, and linezolid to the previously reported efficacy of doxycycline and ciprofloxacin. We demonstrate that treatment with amoxicillin-clavulanic acid, imipenem, vancomycin, and linezolid were as effective as doxycycline and ciprofloxacin, curing rabbits exhibiting bacteremia levels of up to 10(5) CFU/ml. Clarithromycin and rifampin were shown to be effective only as a postexposure prophylactic treatment but failed to treat the systemic (bacteremic) phase of anthrax. Furthermore, we evaluate the contribution of combined treatment of clindamycin and ciprofloxacin, which demonstrated improvement in efficacy compared to ciprofloxacin alone.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26392505      PMCID: PMC4649227          DOI: 10.1128/AAC.01376-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  Anthrax.

Authors:  T C Dixon; M Meselson; J Guillemin; P C Hanna
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

Review 2.  Recognition and management of anthrax--an update.

Authors:  M N Swartz
Journal:  N Engl J Med       Date:  2001-11-06       Impact factor: 91.245

3.  Observations on the prophylaxis of experimental pulmonary anthrax in the monkey.

Authors:  D W HENDERSON; S PEACOCK; F C BELTON
Journal:  J Hyg (Lond)       Date:  1956-03

Review 4.  Anthrax pathogenesis and host response.

Authors:  P Hanna
Journal:  Curr Top Microbiol Immunol       Date:  1998       Impact factor: 4.291

5.  Identification of strain specific markers in Bacillus anthracis by random amplification of polymorphic DNA.

Authors:  Haim Levy; Morly Fisher; Naomi Ariel; Zeev Altboum; David Kobiler
Journal:  FEMS Microbiol Lett       Date:  2005-03-01       Impact factor: 2.742

6.  Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs.

Authors:  Zeev Altboum; Yehoshua Gozes; Ada Barnea; Avi Pass; Moshe White; David Kobiler
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  Oral rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits.

Authors:  M E Shirtliff; J T Mader; J Calhoun
Journal:  Clin Orthop Relat Res       Date:  1999-02       Impact factor: 4.176

8.  Postexposure prophylaxis against experimental inhalation anthrax.

Authors:  A M Friedlander; S L Welkos; M L Pitt; J W Ezzell; P L Worsham; K J Rose; B E Ivins; J R Lowe; G B Howe; P Mikesell
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

9.  Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.

Authors:  Alfred Corey; Thi-Sau Migone; Sally Bolmer; Michele Fiscella; Chris Ward; Cecil Chen; Gabriel Meister
Journal:  Toxins (Basel)       Date:  2013-01-14       Impact factor: 4.546

10.  Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.

Authors:  Daniel B Jernigan; Pratima L Raghunathan; Beth P Bell; Ross Brechner; Eddy A Bresnitz; Jay C Butler; Marty Cetron; Mitch Cohen; Timothy Doyle; Marc Fischer; Carolyn Greene; Kevin S Griffith; Jeannette Guarner; James L Hadler; James A Hayslett; Richard Meyer; Lyle R Petersen; Michael Phillips; Robert Pinner; Tanja Popovic; Conrad P Quinn; Jennita Reefhuis; Dori Reissman; Nancy Rosenstein; Anne Schuchat; Wun-Ju Shieh; Larry Siegal; David L Swerdlow; Fred C Tenover; Marc Traeger; John W Ward; Isaac Weisfuse; Steven Wiersma; Kevin Yeskey; Sherif Zaki; David A Ashford; Bradley A Perkins; Steve Ostroff; James Hughes; David Fleming; Jeffrey P Koplan; Julie L Gerberding
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more
  4 in total

1.  Treating Anthrax-Induced Meningitis in Rabbits.

Authors:  Amir Ben-Shmuel; Itai Glinert; Assa Sittner; Elad Bar-David; Josef Schlomovitz; Tal Brosh; David Kobiler; Shay Weiss; Haim Levy
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.

Authors:  Nicholas J Vietri; Steven A Tobery; Donald J Chabot; Susham Ingavale; Brandon C Somerville; Jeremy A Miller; Chris W Schellhase; Nancy A Twenhafel; David P Fetterer; Christopher K Cote; Christopher P Klimko; Anne E Boyer; Adrian R Woolfitt; John R Barr; Mary E Wright; Arthur M Friedlander
Journal:  J Infect Dis       Date:  2021-02-03       Impact factor: 5.226

3.  Pathology of wild-type and toxin-independent Bacillus anthracis meningitis in rabbits.

Authors:  Assa Sittner; Elad Bar-David; Itai Glinert; Amir Ben-Shmuel; Shay Weiss; Josef Schlomovitz; David Kobiler; Haim Levy
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

4.  Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax.

Authors:  Chad W Stratilo; Scott Jager; Melissa Crichton; James D Blanchard
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.